BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11987242)

  • 21. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
    Hughson MD; He Z; Liu S; Coleman J; Shingleton WB
    Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K; Makino Y; Pereira T; Poellinger L
    EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression.
    Gordeuk VR; Miasnikova GY; Sergueeva AI; Niu X; Nouraie M; Okhotin DJ; Polyakova LA; Ammosova T; Nekhai S; Ganz T; Prchal JT
    Blood; 2011 Nov; 118(19):5278-82. PubMed ID: 21876117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis.
    Cario H; Schwarz K; Jorch N; Kyank U; Petrides PE; Schneider DT; Uhle R; Debatin KM; Kohne E
    Haematologica; 2005 Jan; 90(1):19-24. PubMed ID: 15642664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
    Russell RC; Sufan RI; Zhou B; Heir P; Bunda S; Sybingco SS; Greer SN; Roche O; Heathcote SA; Chow VW; Boba LM; Richmond TD; Hickey MM; Barber DL; Cheresh DA; Simon MC; Irwin MS; Kim WY; Ohh M
    Nat Med; 2011 Jun; 17(7):845-53. PubMed ID: 21685897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K; Zhang N; Zhang K; Na Y
    Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Coinheritance of chromosomes 3 and 11 in the patients with autosomal recessive polycythemia from Chuvachia].
    Vasserman NN; Tverskaia SM; Poliakova AV
    Genetika; 2005 Sep; 41(9):1259-64. PubMed ID: 16240638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on mutations in the HIF: EPO pathway and their role in erythrocytosis.
    Lappin TR; Lee FS
    Blood Rev; 2019 Sep; 37():100590. PubMed ID: 31350093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Homozygous Mutation of the Internal Translation Initiation Start Site of VHL is Exclusively Associated with Erythrocytosis: Indications for Distinct Functional Roles of von Hippel-Lindau Tumor Suppressor Isoforms.
    Bartels M; van der Zalm MM; van Oirschot BA; Lee FS; Giles RH; Kruip MJ; Gitz-Francois JJ; Van Solinge WW; Bierings M; van Wijk R
    Hum Mutat; 2015 Nov; 36(11):1039-42. PubMed ID: 26224408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.